Alembic Pharma Gets USFDA Nod for Generic Schizophrenia Drug
By Rediff Money Desk, New Delhi Sep 27, 2024 15:48
Alembic Pharmaceuticals receives USFDA approval for its generic version of Paliperidone extended-release tablets, indicated for treating schizophrenia. The drug is therapeutically equivalent to Invega.
New Delhi, Sep 27 (PTI) Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia.
The approval by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Paliperidone extended-release tablets of strengths 1.5 mg, 3 mg, 6 mg, and 9 mg, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Invega extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Pharmaceuticals, Inc, it added.
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for the treatment of schizophrenia and it is also indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilisers and/or antidepressants.
Citing IQVIA data, the company said the Paliperidone extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg have an estimated market size of USD 48 million for 12 months ended June 2024.
Alembic Pharma said it has a cumulative total of 215 ANDA approvals (187 final approvals and 28 tentative approvals) from USFDA.
The approval by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Paliperidone extended-release tablets of strengths 1.5 mg, 3 mg, 6 mg, and 9 mg, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Invega extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Pharmaceuticals, Inc, it added.
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for the treatment of schizophrenia and it is also indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilisers and/or antidepressants.
Citing IQVIA data, the company said the Paliperidone extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg have an estimated market size of USD 48 million for 12 months ended June 2024.
Alembic Pharma said it has a cumulative total of 215 ANDA approvals (187 final approvals and 28 tentative approvals) from USFDA.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 10.67 (+ 2.50)
- 69776634
- Spicejet Ltd.
- 58.71 ( -5.06)
- 51299261
- Standard Capital
- 1.52 (+ 9.35)
- 46654145
- GACM Technologies
- 0.95 ( -5.00)
- 28597471
- GTL Infrastructure
- 2.53 (+ 4.98)
- 19162474
MORE NEWS
HCL Technologies Opens New Office in Hyderabad,...
HCL Technologies chairperson Roshni Nadar Malhotra met with Telangana CM A Revanth...
Sustainable Construction Jobs Surge 25% in UAE:...
Demand for workers skilled in sustainable construction practices in the UAE has surged...
Lupin Partners with Celnova for Drug...
Lupin's subsidiary has partnered with Celnova Pharma to distribute NaMuscla, a drug for...